Library & Tools

This graphic provides an overview of how SSA and DDS process disability applications.

A key component of the SOAR model is developing strong collaborations with the Social Security Administration (SSA) and Disability Determination Services (DDS). The SOAR TA Center has created a guide to help!

SOAR programs across the nation are looking for attention-getting ways to communicate with government officials, community providers, potential volunteers, and funders about the work SOAR is doing to help people who are experiencing or at risk of homelessness access Social Security benefits. Most of these stakeholders will look online to find information about your program.

SOAR programs can be funded through a variety of sources, including foundations, private donors, and businesses operating in your communities. 

On this webinar, held on June 6, 2019, we reviewed the many ways OAT can be utilized, beyond outcome tracking.

This webinar, held on January 22, 2020, explored Step 3 and Step 5 of SSA's Sequential Evaluation process -- the only two steps at which an applicant can be found disabled.

The SOAR TA Center has released the outcomes of SSI/SSDI applications submitted using the SOAR process from 2006 through June 30, 2019.

The SOAR TA Center has released the outcomes of SSI/SSDI applications submitted using the SOAR process from 2006 through June 30, 2020.

The CARES Act included additional Emergency Solutions Grants (ESG) funding for communities. There is an opportunity for ESG recipients and Continuums of Care (CoCs) to use some of this funding to support dedicated SOAR case workers.

SSA is now evaluating the long-term effects of COVID-19 when determining disability. On April 16, 2021, SSA issued an Emergency Message (EM) with guidance to its employees for evaluating adult disability cases that include an allegation or diagnosis of COVID-19. Here are the key points of the EM as well as tips for SOAR practitioners to effectively represent SSI/SSDI applicants whose functioning is impacted by COVID-19.